ArticleFrontiers in oncology2019
A Robust 8-Gene Prognostic Signature for Early-Stage Non-small Cell Lung Cancer.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review of Prognostic Gene Signature in Gastric Cancer Patients.Frontiers in bioengineering and biotechnology · 2020Pooled it
- HMMR in human cancers: regulatory mechanism and biological function.Journal of translational medicine · 2025Review
- A machine learning approach for multimodal data fusion for survival prediction in cancer patients.NPJ precision oncology · 2025Article
- Article
- Identification of PANoptosis Subtypes to Assess the Prognosis and Immune Microenvironment of Lung Adenocarcinoma Patients: A Bioinformatics Combined Machine Learning Study.Current cancer drug targets · 2025Article
- Review
- The prognostic and clinical value of genes associate with immunity and amino acid Metabolism in Lung Adenocarcinoma.Heliyon · 2024Article
- Intelligent prognosis evaluation system for stage I-III resected non-small-cell lung cancer patients on CT images: a multi-center study.EClinicalMedicine · 2023Article
- A novel Chr1-miR-200 driven whole transcriptome signature shapes tumor immune microenvironment and predicts relapse in early-stage lung adenocarcinoma.Journal of translational medicine · 2023Article
- A Unique Gene Signature Predicting Recurrence Free Survival in Stage IA Lung Adenocarcinoma.The Journal of thoracic and cardiovascular surgery · 2023Article
- 5-mRNA-based prognostic signature of survival in lung adenocarcinoma.World journal of clinical oncology · 2023Article
- Integrative metabolomics and transcriptomics analysis reveals novel therapeutic vulnerabilities in lung cancer.Cancer medicine · 2023Article
- A novel prognostic model related to oxidative stress for treatment prediction in lung adenocarcinoma.Frontiers in oncology · 2023Article
- Article
- Development and validation of a combined metabolism and immune prognostic model in lung adenocarcinoma.Journal of thoracic disease · 2022Article
- Non-Invasive Biomarkers for Early Lung Cancer Detection.Cancers · 2022Review
- Epigenetic mechanisms of lung carcinogenesis involve differentially methylated CpG sites beyond those associated with smoking.European journal of epidemiology · 2022Article
- Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors.Cancers · 2022Review
- Article
- Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort.Radiation oncology (London, England) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.